{"id":"NCT02189629","sponsor":"Galderma R&D","briefTitle":"CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris","officialTitle":"A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 Âµg/g CREAM IN SUBJECTS WITH ACNE VULGARIS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-23","primaryCompletion":"2017-02-23","completion":"2017-02-23","firstPosted":"2014-07-14","resultsPosted":"2019-09-17","lastUpdate":"2019-11-14"},"enrollment":453,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"CD5789 (trifarotene)","otherNames":[]}],"arms":[{"label":"CD5789 (trifarotene) cream","type":"EXPERIMENTAL"}],"summary":"Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.","primaryOutcome":{"measure":"Investigator Global Assessment (IGA) Success Rate up to Week 52","timeFrame":"From Baseline to Week 52","effectByArm":[{"arm":"CD5789 Cream","deltaMin":453,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":32,"countries":["United States","Czechia","Germany","Hungary"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":453},"commonTop":["Nasopharyngitis","Sunburn","Application Site Pruritis","Application Site Irritation","Upper Respiratory Tract Infection"]}}